MET and non-small cell lung carcinoma: Notably, c-Met overexpression is found in approximately 20 to 25% of NSCLC cases.3,13,14 It is usually assessed by IHC with the SP44 antibody and is scored from 0 to 3+ using a semiquantitative approach.